|
Green Market Report | *|DATE_FORMAT:'%B %d, %Y'|*
|
|
Did someone forward this newsletter to you?
Sign up here to receive the Morning Rise for free.
|
| |
|
|
Lucy Scientific Wants To Buy Pasithea Therapeutics
|
|
Lucy Scientific Discovery Inc. (NASDAQ: LSDI) announced on Monday that it wanted to buy the biotech company Pasithea Therapeutics Corp. (NASDAQ: KTTA) in a cash and stock deal... |
|
|
|
| |
|
Nirvana Moves Forward With MedSmart Acquisition
|
|
Canadian-based psychedelics company Nirvana Life Sciences (CSE: NIRV) has decided to acquire Medsmart Dispensary Inc., which has an exclusive North American license for "SOSA", a patented herbal medicine used for addiction treatment... |
|
|
| |
|
MPM BioImpact to Acquire Reunion Neuroscience for $13.1 Million in All-Cash Deal
|
|
Clinical-stage biopharmaceutical company Reunion Neuroscience Inc. (NASDAQ: REUN) (TSX: REUN) announced Wednesday it has entered into an agreement to be acquired by MPM BioImpact, a global biotechnology investment firm, in an all-cash transaction worth approximately $13... |
|
|
|
| |
|
Compass Pathways Gets Good News on Psilocybin Patent Journey
|
|
Compass Pathways plc (Nasdaq: CMPS) announced that the U.S. Patent Trial and Appeal Board reaffirmed decisions to uphold its ‘257 Patent and ‘259 Patent, key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used in the company’s phase 3 clinical trials... |
|
|
| |
|
Algernon NeuroScience Makes Progress With DMT Study
|
|
Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF)announced that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188 (DMT)... |
|
|
|
| |
|
In Other News |
| Cybin |
| Cybin Inc. (NEO:CYBN) (NYSE American: CYBN), announced changes to its scientific management team. Following the achievement of the final milestones as contemplated by the terms of a contribution agreement dated Dec. 4, 2020, between Cybin and Adelia Therapeutics Inc., a wholly controlled subsidiary of Cybin, Michael Palfreyman and Brett Greene, who joined Cybin as part of the acquisition of Adelia, will leave their roles as chief R&D officer and chief innovations officer, respectively, and transition into advisory roles. Read more here. |
| Terran Biosciences |
| Terran Biosciences, Inc. , a CNS-focused biotech platform company, has entered into an agreement with French pharmaceutical company Pierre Fabre Médicament S.A.S for worldwide exclusive rights to develop and commercialize a pipeline of Pierre Fabre’s assets to treat neuropsychiatric illnesses. Read more here. |
| Psilera |
| A Tampa biotech company hopes to be on the verge of a mental health breakthrough with its research into psychedelic drugs. Psilera is working to develop non-hallucinogenic medications that can be used to treat a wide range of mental health disorders. Read more here. |
| |
|
Events |
| June 19-23: MAPS Psychedelic Science 2023, Denver |
| July 6: Psych Symposium, London |
| July 13-15: PhilaDelic, Philadelphia |
| July 14-16: Sisters in Psychedelics Summit, Vancouver, British Columbia |
| July 14-16: Sisters in Psychedelics Summit, Vancouver, British Columbia |
| Sept. 29-30: PsyCon Colorado, Denver |
| Oct. 5: Psychedealia, New York City |
| |
|
|
